Episode 2 of Our Podcast Out Now: Navigating the AI Revolution in Small Molecule Drug Discovery – Insights with Gavin Hirst

Dear LinkedIn Network,

Exciting news! Episode 2 of "Artificial Intelligence in Healthcare: The Intelligence Roundtable" is now live. This episode, "Unveiling the AI Impact in Drug Discovery," offers an in-depth conversation with Gavin Hirst , a distinguished figure in the world of drug discovery and AI. His bio below:

Gavin is a 30-year drug discovery veteran and is currently the Chief Scientific Officer at Atomwise , a leading AI-enabled drug discovery enterprise on a mission to find a new way to discover medicines.

Gavin’s career spans periods at both large multinational pharmaceutical companies such as 强生公司 , Takeda , and AbbVie in addition to smaller biotechnology ventures. He applied his expertise to bring multiple small molecule drug candidates to the clinic and beyond, spanning 5 different therapeutic areas particularly in Oncology and Immunology. Over the last 2 decades of his career, Gavin has been focused on leveraging predictive tools, such as AI in concert with structure-based drug discovery to bring the highest quality assets to the clinic to impact patients’ lives.

In this episode, we discuss:

• The advancements and challenges in AI-driven drug discovery
• Balancing efficiency and quality in drug development
• Ethical considerations in the AI and healthcare intersection
• Future trends in AI for patient treatment and care

Where to Listen:

• On Spotify
• On Apple Podcasts
• On YouTube

We at Intelligence Ventures are committed to fostering the growth of AI in healthcare. This episode is a part of our effort to bring valuable insights to our community. We encourage you to listen, share, and engage with us in these important discussions.

Your feedback is crucial as we explore the intersection of AI and healthcare. Feel free to reach out for opportunities to collaborate and drive innovation in this exciting field.

Thank you for your continued support. Let's explore the future of AI in healthcare together.

Warm regards,

Doug Nissinoff

Managing Director, Intelligence Ventures

More about Intelligence Ventures

We are an emerging venture capital firm dedicated to cultivating innovation at the intersection of artificial intelligence and healthcare within the United States. Our commitment lies in the strategic investment and nurturing of pre-seed, seed, and Series A companies, fueling their growth and fostering the next generation of industry leaders.

Our initial fund, AI Health Fund I, is focused on companies that use artificial intelligence to increase efficiencies and/or solve computationally intractable problems that place a ceiling on our ability to develop new drugs, advance them through clinical trials, and ultimately diagnose and treat patients. We are industry vertical agnostic and believe that generative AI and more specific ML models can be used to accelerate innovation in biotech, pharma, medtech, and diagnostics.

For more information, visit our website at www.intelligencevc.com or reach out to [email protected] for any inquiries. Be sure to follow us on LinkedIn and Twitter , and subscribe for further installments of The Intelligence Report .